Financial Loss

Showing 2514 articles
Business

Workday's Steep Slide: A Value Bet or Value Trap for Investors?

As the S&P 500 notches another year of robust gains, the concentrated nature of the rally has left some high-flying tech names like Workday in the dust. Hotchkis & Wiley's latest investor letter reveals the HR software giant was a significant drag on its value fund in Q4 2025, with shares down over 33% in a year. Against a backdrop of stretched market valuations, we examine whether this sell-off presents a compelling entry point or signals deeper troubles.

Business

AbCellera Biologics: A Valuation Crossroads After Volatile Returns

Shares of antibody discovery firm AbCellera Biologics (ABCL) present a complex picture for investors, with strong one-year gains overshadowed by steep declines over longer horizons. As the stock trades near $3.86, a significant gap emerges between its market price and some analyst fair value estimates, raising questions about its premium valuation in a challenging biotech market.